AUROPHARMA (Aurobindo Pharma Ltd.): Acquisition / M&A
Aurobindo Pharma has informed the exchange that it proposes to merge two of its wholly owned stepdown subsidiaries — units held through another subsidiary rather than directly — into a wholly owned subsidiary of the company, according to a filing carried by the NSE and timestamped 05 Aug 20:12. The disclosure, as summarised in Strota's data, describes a reshuffle of entities inside the group; it does not name the businesses involved or attach any financial detail.
Strota keeps its own record of how stocks behaved after acquisition and merger disclosures of this type. Across 141 past instances spanning many different companies, the win rate was 48.9% and the average net edge was 0.213% — close to a coin toss once costs are accounted for. That is a base rate for the event category as a whole, not a forecast for this particular stock, and it says nothing about how this specific reorganisation will be received.
The shares closed at ₹1,613.4 on 5 August, up 1.73% from the previous close of ₹1,585.9, on a day the Nifty moved 0.04%. Volume ran about 1.5 times the recent norm, RSI stood at 61.4, and the price sat 1.43% under its 52-week high, above both the 50-day and 200-day moving averages. Futures open interest rose 5.61%. On valuation the pack shows a price-to-earnings ratio of 26.73 and a market capitalisation of ₹92,831 crore.
The same day carried other news. Reuters reported quarterly profit rose on anti-retroviral drug demand, NDTV Profit reported profit up 25% on revenue of ₹9,150 crore, and a separate headline reported a USFDA approval for tofacitinib tablets. With several items landing together, the data does not establish which one moved the price.
The catalyst
Aurobindo Pharma Limited has informed the Exchange about proposal of merger of the two wholly owned stepdown subsidiaries with a wholly owned subsidiary of the Company. (filing · NSE)
What the data shows after this event
Across Strota's backtest of past filings, Acquisition / M&A shows no reliable next-session edge — the move went bullish in about 48.9% of next sessions (net 0.213% after drift and cost, n=141). A base rate, not a forecast for this stock.
AUROPHARMA right now
trading +1.73% on the day; F&O shows Long Buildup (OI 5.61% ); P/E 26.73; RSI 61.4. Full AUROPHARMA analysis →
Sources
- Aurobindo Pharma Limited has informed the Exchange about proposal of merger of the two wholly owned stepdown subsidiaries with a wholly owned subsidiary of the Company. — NSE
- India's Aurobindo Pharma posts quarterly profit rise on anti-retroviral drug demand — Reuters
- Aurobindo Pharma Q1 Results: Profit Jumps 25%, Revenue Rises To Rs 9,150 Crore; Margins Improve — NDTV Profit
- Upcoming Stock Split, Dividend, Bonus Issue THIS Week: Aurobindo Pharma, Muthoot Finance, More | Full List — Goodreturns
- Merck (MRK) Is Up 5.4% After Expanding HIV PrEP Access And Launching Oral Cholesterol Drug — Simply Wall St.
Keep digging
- AUROPHARMA — full smart-money page: F&O positioning, deals, insider filings and option chain in one place.
- Today's screens: every stock matching the same setups (buildups, breakouts, volume shockers).
- Newsroom: the other stocks in play this session.